You are here: Home » Companies » News
Business Standard

Shasun Pharma, SeQuent ink deal on veterinary products manufacturing

The deal will also be an exposure for Shasun into the veterinary medicine segment, where it has not been operating so far, according to company officials

BS Reporter  |  Chennai 

Chennai-based Shasun Pharmaceuticals Ltd has signed a letter of intent (LoI) with Bangalore-based pharmaceutical firm SeQuent Scientific Ltd to develop, manufacture and sell veterinary products, including active pharmaceutical ingredients (API) and formulations, in the global market.

The partners would set up a joint venture company, of which 73 per cent would be owned by SeQuent and 27 per cent by Shasun. Contributions will be made by both the by way of transfer of identified assets, contracts and licences.

This would also be an exposure for Shasun into the veterinary medicine segment, where it has not been operating so far, according to company officials.

"We have signed an LoI and the rest of the procedures will follow. We are expecting the JV company to be ready for operation by March 2014," said S Hariharan, chief financial officer, Shasun Pharmaceuticals Ltd.

While the company does not have an exposure in the segment, it would bring in contacts that could be used for the growth of the JV, he added.

The JV firm would also have a manufacturing facility in Visakhapatnam, where Shasun is currently developing its manufacturing facilities. It plans to sell the products to both domestic and export markets, he said.

In a statement, Gautam Kumar Das, joint managing director of SeQuent said: "The combination with Shasun will deliver synergies and technical arbitrage enabling the JV to emerge as a leading global provider of animal health solutions."

SeQuent Scientific has presence in various pharmaceutical segments including APIs, animal health, analytical services, contract research and manufacturing services, and speciality chemicals. The company claims to be the world's largest producer of anthelmintics (a drug used to treat infections caused by parasitic worms) and a strong player in the veterinary API business.

Shasun Pharma manufactures active pharmaceutical ingredients and formulations and offers contract research and manufacturing services for APIs in India and the UK.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, July 14 2013. 20:44 IST